News
SHANGHAI, China I June 9, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical ...
2d
MedPage Today on MSNNovel IgA Nephropathy Injectable Halved ProteinuriaA novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.
The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...
In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...
New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...
New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...
5d
Verywell Health on MSN17 Causes of Foamy Pee and When to Seek TreatmentMedically reviewed by Matthew Wosnitzer, MD Foamy pee may be a sign of proteinuria, a condition in which protein ...
Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...
Recently, I almost experienced kidney failure from a probable infection. I am a male, age 68. My glomerular filtration rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results